Fecal matter for prevention or treatment of autoimmune diseases

Max Nieuwdorp (Inventor), W.M. de Vos (Inventor)

Research output: PatentOther research output

Abstract

The present invention relates to the use of fecal matter in the treatment of a subject having autoimmune disease, wherein the fecal matter is autologous to the subject, and preferably administered to the small intestine, preferably the duodenum, of the subject. The fecal matter can be one or more constituents of autologous feces, preferably chosen from the group consisting of bacteria, viruses, bacteriophages, fungi, metabolites, microRNAs, proteins, antibodies, and/or antigens.
Original languageEnglish
Patent numberWO2019168401
Priority date20/07/18
Publication statusPublished - 6 Sep 2019

Fingerprint

MicroRNAs
Duodenum
Feces
Bacteriophages
Autoimmune Diseases
Small Intestine
Fungi
Viruses
Bacteria
Antigens
Antibodies
Proteins

Cite this

@misc{d900e2499da44a798b35a59af266388f,
title = "Fecal matter for prevention or treatment of autoimmune diseases",
abstract = "The present invention relates to the use of fecal matter in the treatment of a subject having autoimmune disease, wherein the fecal matter is autologous to the subject, and preferably administered to the small intestine, preferably the duodenum, of the subject. The fecal matter can be one or more constituents of autologous feces, preferably chosen from the group consisting of bacteria, viruses, bacteriophages, fungi, metabolites, microRNAs, proteins, antibodies, and/or antigens.",
author = "Max Nieuwdorp and {de Vos}, W.M.",
year = "2019",
month = "9",
day = "6",
language = "English",
type = "Patent",
note = "WO2019168401",

}

Fecal matter for prevention or treatment of autoimmune diseases. / Nieuwdorp, Max (Inventor); de Vos, W.M. (Inventor).

Patent No.: WO2019168401.

Research output: PatentOther research output

TY - PAT

T1 - Fecal matter for prevention or treatment of autoimmune diseases

AU - Nieuwdorp, Max

AU - de Vos, W.M.

PY - 2019/9/6

Y1 - 2019/9/6

N2 - The present invention relates to the use of fecal matter in the treatment of a subject having autoimmune disease, wherein the fecal matter is autologous to the subject, and preferably administered to the small intestine, preferably the duodenum, of the subject. The fecal matter can be one or more constituents of autologous feces, preferably chosen from the group consisting of bacteria, viruses, bacteriophages, fungi, metabolites, microRNAs, proteins, antibodies, and/or antigens.

AB - The present invention relates to the use of fecal matter in the treatment of a subject having autoimmune disease, wherein the fecal matter is autologous to the subject, and preferably administered to the small intestine, preferably the duodenum, of the subject. The fecal matter can be one or more constituents of autologous feces, preferably chosen from the group consisting of bacteria, viruses, bacteriophages, fungi, metabolites, microRNAs, proteins, antibodies, and/or antigens.

M3 - Patent

M1 - WO2019168401

ER -

Nieuwdorp M, de Vos WM, inventors. Fecal matter for prevention or treatment of autoimmune diseases. WO2019168401. 2019 Sep 6.